Regado provides additional phase-2b data on RB006/RB007 anticoagulant and reversing agent: http://finance.yahoo.com/news/Regado-Biosciences-Inc-prnews-3336913480.html?x=0&.v=1 The main results from this phase-2b trial were presented at ACC in Mar 2011 (#msg-61433660).